KindlyMD, Inc. (NASDAQ:NAKA - Get Free Report) was the target of a large increase in short interest in September. As of September 15th, there was short interest totaling 12,760,000 shares, an increase of 768.0% from the August 31st total of 1,470,000 shares. Based on an average daily trading volume, of 7,270,000 shares, the short-interest ratio is presently 1.8 days. Approximately 3.6% of the shares of the stock are short sold. Approximately 3.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 7,270,000 shares, the short-interest ratio is presently 1.8 days.
Analyst Upgrades and Downgrades
Separately, Maxim Group started coverage on KindlyMD in a research report on Wednesday, September 3rd. They set a "buy" rating and a $8.00 price target on the stock. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $8.00.
Get Our Latest Stock Analysis on KindlyMD
KindlyMD Price Performance
Shares of NAKA opened at $1.07 on Wednesday. The company has a market cap of $442.55 million, a price-to-earnings ratio of -1.24 and a beta of 33.96. The company has a fifty day moving average price of $6.61. KindlyMD has a 52 week low of $0.65 and a 52 week high of $34.77.
KindlyMD (NASDAQ:NAKA - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.34) earnings per share (EPS) for the quarter. KindlyMD had a negative return on equity of 131.09% and a negative net margin of 244.00%.The company had revenue of $0.41 million during the quarter.
About KindlyMD
(
Get Free Report)
Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider KindlyMD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KindlyMD wasn't on the list.
While KindlyMD currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.